PKD Cures Act
Rep. Wasserman Schultz Introduces Bipartisan PKD Cures Act to Tackle $3 Billion Kidney Disease Crisis
The PKD Cures Act is currently in the early stages of the legislative process. It was recently sent to the House Committee on Energy and Commerce for review. No further actions are scheduled at this time, so the bill is currently waiting for committee members to consider it.
Legislative Progress
This bill has support from both Democrats and Republicans, which helps its chances. However, many bills that focus on specific diseases face a long road to becoming law because of budget limits.
Key Points
Impact Analysis
Personal Impact
Programs
PKD-related kidney failure costs Medicare roughly $3 billion per year. If the expanded research leads to treatments that prevent or delay kidney failure, Medicare could see significant long-term savings by reducing the number of patients needing expensive dialysis and transplants. However, this outcome depends on successful research breakthroughs, which are inherently uncertain.
“End-stage renal disease and kidney failure attributable to cystic kidney diseases, like PKD, cost Medicare an estimated $3,000,000,000 annually.”
Disabilities
Milestones
Referred to the House Committee on Energy and Commerce.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
Source Information
Document Type
Congressional Bill
Official Title
PKD Cures Act
Data Sources
Sponsor
Cosponsors
(3)Analysis generated by AI. Always verify with official sources.